 Use recombinant human conjunction syngeneic bone marrow transplantation mice model control minimal residual disease malignant hematologic disorders allogeneic bone marrow transplantation BMT autologous BMT immune-mediated graft-versus-leukemia GVL effects hence relapse rate autologous BMT malignant hematologic disorders allogeneic BMT Autologous BMT medical procedure available many patients need situations allogeneic BMT feasible risky present experiments possible therapeutic benefits autologous BMT additional immunotherapy BMT tumor model GVL effects murine B-cell leukemia spontaneous nonimmunogenic lethal leukemia BALB/c origin BALB/c mice leukemia cells cyclophosphamide mg/kg normal syngeneic BM cells day High-dose recombinant Cetus units consecutive days day BMT Kinetics lymphocyte reconstitution syngeneic BMT steep increase absolute number peripheral blood lymphocytes days experimental groups relapse Mice therapy days BMT whereas mice long-term disease-free survival Optimal time administration weeks post-BMT mice evidence disease year cells day syngeneic BMT minimal residual disease syngeneic BMT therapy days effective disease-free survival contrast regimen day BMT data immunotherapy new immunotherapeutic tool relapse rate BMT hematologic malignancies